PCI Biotech Holding ASA, of Oslo, Norway, reported results from a Phase I/II study of combination product PC-A11, which combines the photosensitizer Amphinex with the cytotoxic agent bleomycin. The drug was well tolerated, and a dose-limiting toxicity of skin photosensitivity and ulceration occurred at the fourth dose level. Complete clinical regression of target tumors was seen in 14 of 16 patients completing the first assessment and eight of 11 patients completing the second assessment.